IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ImmunityBio Inc (IBRX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and expanding market opportunities, the technical indicators and financial performance suggest caution. The stock lacks strong proprietary trading signals, and the current pre-market price trend is slightly negative. Additionally, the company's financials show significant net losses and declining EPS, which may not align with the user's investment goals.
The MACD is negative and expanding (-0.0809), indicating bearish momentum. The RSI is neutral at 46.384, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level (S1: 8.592), with resistance levels at R1: 11.732 and R2: 12.702. However, the pre-market price is down by -0.22%, and the stock has a 30% chance to decline in the next week.
Analysts have raised price targets significantly, with Piper Sandler increasing to $12 and H.C. Wainwright to $15, citing strong revenue growth and regulatory approvals.
The company's Anktiva product has expanded into new markets, including the EU and Saudi Arabia, with projected revenues of $195M in
The FDA fast-tracked approvals for related therapies, which could enhance market sentiment.
The company reported a severe shortage of BCG, which may delay treatments and impact market share.
The stock fell over 7% recently, reflecting negative market sentiment.
Financials show a net loss of -$61.94M in Q4 2025, with declining EPS (-25% YoY).
In Q4 2025, revenue increased by 406.95% YoY to $38.29M, showing strong growth. However, the company reported a net loss of -$61.94M, with EPS dropping by -25% YoY to -0.06. Gross margin slightly declined to 99%. While revenue growth is impressive, the persistent losses and declining EPS are concerning.
Analysts are bullish on IBRX, with recent upgrades in price targets from Piper Sandler ($12), H.C. Wainwright ($15), and Jefferies ($9). They highlight strong revenue growth, regulatory approvals, and market expansion opportunities. However, the stock's recent performance and financial losses may temper enthusiasm.
